VRNA
Verona Pharma Plc
Halal Rating :
Last Price
$51.77
Last updated:
Market Cap
-
7D Change
10.88%
1 Year Change
202.22%
Company Overview
Industries
Exchange
Next Earnings Date
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their lead product candidate is ensifentrine, a first-in-class treatment being developed for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The company is in late-stage clinical development and preparing for potential commercialization.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $5.62m | $56.17m | - | $9.88m | 0.00% | 17.59% |
Company Impact
Help us evaluate Verona Pharma Plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.